- Clinical Trials
- Research News
- Industry Trends
- Agency Actions
- Drug Safety Issues
- Approvals, Launches, & New Indications
- Health Care Reform
New Vaccine Candidate for Deadly H7N9 Flu Virus
Thirty-one deaths reported in China (May 8)
A new virus-like particle (VLP) vaccine candidate has been produced for the avian influenza A (H7N9) virus that is responsible for the current deadly flu outbreak in China.
In order to produce an influenza vaccine, the manufacturer — Medicago Inc., based in North Carolina and Canada — requires only the genetic sequence of the viral strain, thus limiting the delays that can occur using traditional manufacturing systems. Manufacturers of current egg-based flu vaccines can take up to 6 months to produce a vaccine for any new strain.
The new H7N9 VLP vaccine is currently being purified in preparation for immunogenicity studies in animal models.
To date, a total of 130 laboratory-confirmed cases of human infection with the H7N9 virus strain, including 31 deaths, have been reported to the World Health Organization (WHO).
Source: Medicago Inc.; May 8, 2013.